Pharvaris to Make a Splash at Healthcare Conference
Pharvaris, renowned for its commitment to addressing hereditary angioedema (HAE) through innovative therapies, has announced its participation in the Inaugural Guggenheim Securities Healthcare Innovation Conference. This significant event will take place during a three-day period featuring leading advancements in healthcare innovation. It brings together experts and stakeholders focusing on groundbreaking medical developments.
Details of the Conference Appearance
Pharvaris’ management team is set to engage in a fireside chat scheduled for a Wednesday morning session. This format promises an interactive discussion that will shed light on the company's latest research and innovations surrounding its oral bradykinin B2 receptor antagonists, which are designed to prevent and treat HAE attacks.
Live Audio Webcast Available
The audio from the fireside chat will be accessible via a live webcast. Interested parties can tune in through the Investors section of the Pharvaris website. For those who cannot attend the live session, the company has ensured that an audio replay will be available for 30 days after the event, allowing a broader audience to benefit from the insights shared.
About Pharvaris and Its Mission
Pharvaris is on a mission to transform treatments for HAE sufferers. The company's focus is on developing novel, oral therapies that can effectively manage HAE attacks. The pioneering bradykinin B2 receptor antagonists they are developing aim to offer patients a much-needed alternative to existing treatments. These advancements seek to not only provide on-demand relief but also preventative care, enhancing the overall quality of life for those affected by this debilitating condition.
Progress in Therapeutic Development
Currently, Pharvaris is advancing its investigational product, deucrictibant, which is already showing promising results in both Phase 2 studies focused on prophylaxis and on-demand treatment scenarios. Encouraged by positive feedback from these trials, the company is poised to enroll participants in a pivotal Phase 3 study, aiming to provide a robust treatment option for HAE attacks.
Future Pathways and Strategic Vision
The strategic roadmap for Pharvaris is ambitious, with plans to initiate another pivotal Phase 3 study by the year’s end. This upcoming study will hone in on the preventative features of deucrictibant, demonstrating the company's commitment to addressing HAE in a comprehensive manner. Pharvaris is dedicated to working closely with healthcare professionals and patients alike to ensure these innovative solutions are effective and accessible.
Contact for Further Information
Those interested in delving deeper into Pharvaris' innovative work can refer to their official site for further updates and resources. The company is proud to present findings that have the potential to reshape the medical landscape for HAE treatments and continue to foster open communication with stakeholders in the healthcare community.
Frequently Asked Questions
What is the purpose of the Guggenheim Healthcare Innovation Conference?
The conference aims to present the latest advancements in healthcare innovation by bringing together industry experts and leading companies to discuss their innovations and research.
What type of therapies does Pharvaris develop?
Pharvaris focuses on developing novel oral bradykinin B2 receptor antagonists aimed at preventing and treating hereditary angioedema attacks.
How can I access the webcast of the Pharvaris presentation?
The live audio webcast can be accessed through the Investors section of Pharvaris’ website, along with a replay available for 30 days after the event.
What is deucrictibant?
Deucrictibant is Pharvaris’ investigational therapeutic, currently in development for the on-demand treatment of HAE attacks, showcasing promising efficacy in clinical trials.
What are the future plans for Pharvaris regarding HAE treatment?
Pharvaris plans to initiate a pivotal Phase 3 study for deucrictibant’s preventive treatment of HAE attacks by the end of the year, indicating robust growth and proactive strategy in addressing patient needs.
